Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.
Legge, F., Paglia, A., D'Asta, M., Fuoco, G., Scambia, G., Ferrandina, M. G., Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients, <<BMC CANCER>>, 2011; 11 (Maggio): 214-214. [doi:10.1186/1471-2407-11-214] [http://hdl.handle.net/10807/3721]
Phase II study of the combination carboplatin plus celecoxib in heavily pre-treated recurrent ovarian cancer patients
Legge, Francesco;Paglia, Amelia;D'Asta, Marco;Fuoco, Gilda;Scambia, Giovanni;Ferrandina, Maria Gabriella
2011
Abstract
Cyclooxygenase-2 overexpression is associated with poor outcome and resistance to platinum-based chemotherapy in ovarian cancer. We evaluated the antitumor activity and safety of the combination carboplatin plus the COX-2 inhibitor celecoxib in recurrent heavily-treated OC patients.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
